We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$782M
AUM Growth
+$134M
Cap. Flow
-$119M
Cap. Flow %
-15.2%
Top 10 Hldgs %
66.62%
Holding
166
New
28
Increased
41
Reduced
46
Closed
40

Top Buys

Rank Stock Value
1
ORMP icon
Oramed Pharmaceuticals
ORMP
+$4.16M
2
NKTR icon
Nektar Therapeutics
NKTR
+$3.04M
3
VKTX icon
Viking Therapeutics
VKTX
+$1.95M
4
FOLD
Amicus Therapeutics
FOLD
+$1.63M
5
GNPX icon
Genprex
GNPX
+$1.42M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$40.1M
2
NVO
Novo Nordisk
NVO
+$19.8M
3
SSKN
Strata Skin Sciences
SSKN
+$3.45M
4
INCY icon
Incyte
INCY
+$2.77M
5
AZN icon
AstraZeneca
AZN
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 15.01%
2 Consumer Staples 0.29%
3 Financials 0.12%
4 Technology 0.09%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVM icon
101
CEL-SCI Corp
CVM
$21M
$101K 0.01%
827
+274
+50% +$15.8K
AYTU icon
102
AYTU BioPharma
AYTU
$22.9M
$98K 0.01%
177
– –
SLS icon
103
SELLAS Life Sciences
SLS
$1.98B
$96K 0.01%
+1,566
New +$108K
SGLBW
104
DELISTED
Sigma Labs, Inc. Warrant
SGLBW
$87K 0.01%
280,529
-3,800
-1% -$1.25K
DRRX
105
CALL
DELISTED
DURECT Corp
DRRX
$69K 0.01%
63
+2
+3% +$27
YTEN
106
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$68K 0.01%
50
– –
RXIIW
107
DELISTED
RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
$68K 0.01%
195,259
-963
-0.5% -$458
ONTXW
108
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$67K 0.01%
665,470
+11,451
+2% +$1.83K
EDSA icon
109
Edesa Biotech
EDSA
$47.9M
$65K 0.01%
+1,116
New +$71.1K
SCYX icon
110
SCYNEXIS
SCYX
$36M
$50K 0.01%
+520
New +$61.4K
PPBT
111
Purple Biotech
PPBT
$1.28M
$47K 0.01%
+14
New +$55.4K
PLUR icon
112
PUT
Pluri
PLUR
$18.1M
$41K 0.01%
4
– –
SOLOW
113
DELISTED
Electrameccanica Vehicles Corp. Ltd. Warrants
SOLOW
$38K ﹤0.01%
+101,000
New +$51.6K
OPGN
114
DELISTED
OpGen, Inc
OPGN
$34K ﹤0.01%
4
-57
-93% -$441K
ISEE
115
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$31K ﹤0.01%
133
– –
CRMD icon
116
PUT
CorMedix
CRMD
$577M
$28K ﹤0.01%
+57
New +$140
CTXR icon
117
Citius Pharmaceuticals
CTXR
$13.7M
$20K ﹤0.01%
463
-15,824
-97% -$756K
RSLS
118
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
$20K ﹤0.01%
3,298
+1,616
+96% +$139K
NSPRZ
119
DELISTED
InspireMD, Inc. Series B Warrants
NSPRZ
$7K ﹤0.01%
1,847,636
-134,681
-7% -$1.21K
BNTCW
120
DELISTED
Benitec Biopharma Limited
BNTCW
$7K ﹤0.01%
58,050
-17,854
-24% -$8.3K
NSPRW
121
DELISTED
InspireMD, Inc. Warrants
NSPRW
$1K ﹤0.01%
498,797
-339,180
-40% -$2.31K
ADVM
122
DELISTED
Adverum Biotechnologies
ADVM
– –
-2,726
Closed -$153K
AFMD
123
CALL
DELISTED
Affimed
AFMD
– –
-54
Closed -$90K
AFMD
124
DELISTED
Affimed
AFMD
– –
-8,639
Closed -$143K
AFMD
125
PUT
DELISTED
Affimed
AFMD
– –
-45
Closed -$75K
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sabby Management held 166 positions worth $782M, up 21% from $647M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $119M in Q3 2018, closing 40 positions and reducing 46 holdings. Its most notable exit was Novo Nordisk, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 26% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Sabby Management opened a new position in Oramed Pharmaceuticals worth $3.88M.

  • Sabby Management's largest Q3 2018 buy was Oramed Pharmaceuticals: 801,242 shares worth $3.88M.
  • Sabby Management added most to Nektar Therapeutics in Q3 2018, an estimated $3.04M increase.
  • Sabby Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $40.1M.
  • Sabby Management fully exited Novo Nordisk in Q3 2018, selling an estimated $19.8M.
  • Sabby Management's ten largest holdings make up 67% of its $782M portfolio in Q3 2018.
  • Sabby Management opened 28 new positions and closed 40 in Q3 2018.
  • Sabby Management's portfolio value rose 21% quarter-over-quarter to $782M.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.